| ABSTRACT Objective:To analyze post marketing off label uses and adverse reactions of apatinib mesylate tablets in the clinical use, and to provide references for rational drug use in the clinic. Methods:We conducted a retrospective medical record review of 33 inpatients with application of apatinib mesylate tablets from September 2015 to July 2017 in a hospital, and analyzed the characters of the patient sex, age, primary tumor, dosage and administration and adverse drug reaction/event (ADR/ADE) etc. Results: The off label ratios of the indications for apatinib mesylate tablets were 57.58% (19 patients). The clinical common dose of apatinib mesylate tablets was 250 mg or 500 mg, less than the dose of 850 mg recommended in drug instruction. The rate of adverse events were 48.48%, mostly grade 1, 2 or 3. And they were mainly blood and lymphatic system disorders, hypertension and alimentary tract hemorrhage. Conclusion:Most of the medical order of apatinib mesylate tablets was involved in the off label drug use. The rate of adverse events were 48.48%. And most of these ADRs could be controlled by suspending administration, adjusting dosage or symptomatic treatment. |
